Completed
Trimetrexate Glucuronate and Leucovorin Treatment for Pneumocystis Carinii Pneumonia
What is being tested
Trimetrexate glucuronate
+ Leucovorin calcium
Drug
Who is being recruted
Blood-Borne Infections+22
+ Urogenital Diseases
+ Genital Diseases
Over 2 Years
+6 Eligibility Criteria
How is the trial designed
Treatment Study
Interventional
Summary
Principal SponsorU.S. Bioscience
Last updated: June 24, 2005
Sourced from a government-validated database.Claim as a partner
Patients receive intravenous infusions of trimetrexate glucuronate and leucovorin for 21 days. Leucovorin is continued for 3 additional days after discontinuation of trimetrexate glucuronate. Patients are followed for 1 month.
Principal SponsorU.S. Bioscience
Last updated: June 24, 2005
Sourced from a government-validated database.Claim as a partner
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.Treatment Study
These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Conditions
Criteria
Any sex
Biological sex of participants that are eligible to enroll.Over 2 Years
Range of ages for which participants are eligible to join.Healthy volunteers not allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
Blood-Borne InfectionsUrogenital DiseasesGenital DiseasesBacterial Infections and MycosesCommunicable DiseasesImmunologic Deficiency SyndromesImmune System DiseasesInfectionsLung DiseasesLung Diseases, FungalMycosesPneumoniaRespiratory Tract DiseasesRespiratory Tract InfectionsRetroviridae InfectionsRNA Virus InfectionsSexually Transmitted DiseasesSlow Virus DiseasesVirus DiseasesSexually Transmitted Diseases, ViralLentivirus InfectionsPneumocystis InfectionsAcquired Immunodeficiency SyndromePneumonia, PneumocystisHIV Infections
Criteria
5 inclusion criteria required to participate
Consent of parent or guardian if less than 18 years of age
Patients must have Pneumocystis carinii pneumonia (PCP) confirmed within 15 days prior to study entry
Patients must have serious intolerance and/or resistance to standard therapies (such as trimethoprim/sulfamethoxazole and parenteral pentamidine) during the course of therapy for the current episode of PCP, or a documented history of such intolerance during a prior episode
Pregnant women may enroll after the physician and patient have discussed the potential benefit versus risk
Show More Criteria
1 exclusion criteria prevent from participating
History of Type I hypersensitivity (i.e., urticaria, angioedema, or anaphylaxis), exfoliative dermatitis, or other life-threatening reactions due to trimetrexate glucuronate
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has 1 location
United States Bioscience Inc
West Conshohocken, United StatesOpen United States Bioscience Inc in Google MapsCompletedOne Study Center